Britta Stordal

Britta Stordal

UNVERIFIED PROFILE

Are you Britta Stordal?   Register this Author

Register author
Britta Stordal

Britta Stordal

Publications by authors named "Britta Stordal"

Are you Britta Stordal?   Register this Author

23Publications

-Reads

Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.

Exp Cell Res 2015 Aug 12;336(1):1-14. Epub 2014 Dec 12.

Department of Histopathology, Trinity College Dublin, Central Pathology Laboratory, St James's Hospital, Dublin 8, Ireland; Department of Natural Sciences, Hendon Campus, Middlesex University, London NW4 4BT, United Kingdom. Electronic address:

View Article
August 2015

Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines.

MethodsX 2015 25;2:8-13. Epub 2014 Nov 25.

Department of Histopathology, Trinity College Dublin, Central Pathology Laboratory, St. James's Hospital, Dublin 8, Ireland ; Department of Natural Sciences, Hendon Campus, Middlesex University, London NW4 4BT, United Kingdom.

View Article
July 2015

Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.

BMC Cancer 2015 Jul 25;15:547. Epub 2015 Jul 25.

Department of Histopathology TCD, Sir Patrick Dun's Laboratory, Central Pathology Laboratory, St James's Hospital, Dublin 8, Ireland.

View Article
July 2015

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.

Mol Cancer 2014 Oct 24;13:241. Epub 2014 Oct 24.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article
October 2014

PARP Inhibitors as P-glyoprotein Substrates.

J Pharm Sci 2014 Jun 3;103(6):1913-20. Epub 2014 Apr 3.

Department of Histopathology, St James' Hospital and Trinity College, Dublin, Dublin 8, Ireland.

View Article
June 2014

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.

Front Oncol 2014 6;4:40. Epub 2014 Mar 6.

National Institute for Cellular Biotechnology, Dublin City University , Dublin , Ireland ; Department of Histopathology, St James' Hospital, Trinity College Dublin , Dublin , Ireland.

View Article
March 2014

Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells.

Anticancer Res 2014 Jan;34(1):503-7

Department of Histopathology, Trinity College Dublin, 1.18 Sir Patrick Dun Research Laboratory, Central Pathology Building, St James' Hospital, Dublin 8, Ireland.

View Article
January 2014

Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.

PLoS One 2012 11;7(7):e40717. Epub 2012 Jul 11.

National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.

View Article
January 2013

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Drug Resist Updat 2011 Jun 24;14(3):177-90. Epub 2011 Mar 24.

National Institute for Cellular Biotechnology, Dublin City University, Ireland.

View Article
June 2011

Citations, citations everywhere but did anyone read the paper?

Authors:
Britta Stordal

Colloids Surf B Biointerfaces 2009 Sep 10;72(2):312; author reply 313. Epub 2009 Apr 10.

View Article
September 2009

A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.

Curr Cancer Drug Targets 2009 May;9(3):354-65

National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article
May 2009

ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.

Cancer Chemother Pharmacol 2009 Mar 25;63(4):661-72. Epub 2008 Jun 25.

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and The University of Sydney, St Leonards, NSW, Australia.

View Article
March 2009

Platinum resistance needs the mythbusters.

Toxicol Lett 2008 Aug 10;180(3):230. Epub 2008 Jul 10.

View Article
August 2008

A 39 kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome.

IUBMB Life 2008 Mar;60(3):180-4

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and University of Sydney, Australia.

View Article
March 2008

A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.

Cancer Treat Rev 2007 Dec 18;33(8):688-703. Epub 2007 Sep 18.

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and The University of Sydney, St. Leonards, NSW 2065, Australia.

View Article
December 2007

Understanding cisplatin resistance using cellular models.

IUBMB Life 2007 Nov;59(11):696-9

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and University of Sydney, St Leonards, New South Wales, Australia.

View Article
November 2007

Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.

Cancer Treat Rev 2007 Jun 23;33(4):347-57. Epub 2007 Mar 23.

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and University of Sydney, St. Leonards, NSW 2065, Australia.

View Article
June 2007

Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.

Genes Chromosomes Cancer 2006 Dec;45(12):1094-105

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia.

View Article
December 2006

Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.

Cancer Chemother Pharmacol 2006 Aug 10;58(2):256-65. Epub 2005 Nov 10.

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital, 2065 St Leonards, NSW, Australia.

View Article
August 2006